RxDoctor Payments Data

Karlton Wong, MD

Hematology & Oncology · Burbank, CANPI 1376962381

Payments from drug & device makers

$420,328in general payments, 2019–2025

Across 111 payments — averaging $3786.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$320K
  • AbbVie$27K
  • Janssen Research & Development, LLC$24K
  • Seagen Inc.$16K
  • Pfizer$15K
  • Eli Lilly$13K
  • plus $5K from 18 others

What the payments were for

  • Consulting fees$82529%
  • Food & beverage$2,03570%
  • Education$311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$420,328 in reported general payments places this provider in the 80th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California

Medicare billing

Part B allowed, 2024
$908,304
Medicare patients
520
Services billed
30,287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide45$746,120
VerzenioAbemaciclib23$443,435
Lenalidomide27$388,425
IbrancePalbociclib24$328,180
ZejulaNiraparib Tosylate12$202,971
CalquenceAcalabrutinib Maleate12$184,229
BrukinsaZanubrutinib11$169,483
Imatinib Mesylate13$149,872
EliquisApixaban121$103,861
JakafiRuxolitinib Phosphate11$88,495
XareltoRivaroxaban24$18,258
Diclofenac Sodium15$4,216
Exemestane30$2,025
Anastrozole92$1,778
Enoxaparin Sodium15$1,569

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$26$746,12045 claims
PfizerIbrance, Eliquis$15,114$432,041145 claims
GSKZejula$891$202,97112 claims
Incyte CorporationJakafi$24$88,49511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,363 hematology & oncology providers in California.

Other hematology & oncology in Burbank

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →